What do systematic reviews say?

Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone

Imiquimod 5% cream with tazarotene 0.1% gel may leads to higher secondary outcome: Inflammatory response (number of lesions with… compared with imiquimod 5% cream alone (low certainty).

• Interventions for melanoma in situ, including lentigo maligna 2014 · Cochrane Headline outcomes only
  RR 1.38 [1.04, 1.84]
  1 study · 88 participants
  Low

Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone

Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in primary outcome: Histological complete response (intention‐to‐treat)… compared with imiquimod 5% cream alone (low certainty).

• Interventions for melanoma in situ, including lentigo maligna 2014 · Cochrane Headline outcomes only
  RR 1.12 [0.81, 1.55]
  1 study · 90 participants
  Low
• Interventions for melanoma in situ, including lentigo maligna 2014 · Cochrane Headline outcomes only
  RR 1.19 [0.9, 1.57]
  1 study · 78 participants
  Low

Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone

Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).

• Interventions for melanoma in situ, including lentigo maligna 2014 · Cochrane Headline outcomes only
  RR 6.27 [0.79, 50.02]
  1 study · 90 participants
  Low

Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone

• Interventions for melanoma in situ, including lentigo maligna 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 88 participants
  Low